Iconovo, ISR to develop inhaled COVID-19 vaccine

By The Science Advisory Board staff writers

April 1, 2021 -- Iconovo announced it has signed an agreement with Immune System Regulation (ISR) that gives ISR exclusive rights to use Iconovo's ICOone inhaler for the treatment of COVID-19 and its variants.

The agreement is Iconovo's second that provides rights to use its inhalation product and confirms the suitability of the ICOone inhaler for vaccines, according to the company. Iconovo will develop an adjuvanted inhalation product with the goal of testing it in clinical trials targeted to start during the second half of 2021. ISR also receives an option to use its vaccination technology in ICOone for influenza, respiratory syncytial virus, and new strands of SARS-CoV-2 virus vaccines based on the same technology.

The agreement will include stepwise payments of an over $10 million technology access fee, set up as five increasing milestone payments over the development to market authorization. ISR will also pay Iconovo for the contract development of the inhalation product. The agreement will additionally give Iconovo low single-digit percentage royalties over a period of 14 years from launch.

Iconovo was founded in 2013 to develop inhalers and associated drug preparations used to treat asthma and chronic obstructive pulmonary disease (COPD).

GSK, CureVac collaborate on next-gen multivalent mRNA COVID-19 vaccines
Glaxo Smith Kline (GSK) and CureVac have entered into a collaboration to jointly develop next-generation messenger RNA (mRNA) vaccines for COVID-19, with...
Synthetic chemistry can help speed protein subunit vaccine development
A new method using synthetic chemistry can be a powerful tool for efficiently building adjuvanted protein-based subunit vaccines against a variety of...
ImmunityBio licenses oral vaccine tech from IosBio
ImmunityBio has signed an exclusive worldwide licensing agreement for IosBio's OraPro vaccine platform technology that is currently being investigated...
Bharat, TJU partnering on COVID-19 vaccine
Bharat Biotech and Thomas Jefferson University (TJU) of Philadelphia have signed a deal to develop a new vaccine for COVID-19.
COVID-19 vaccine candidates show progress amid challenges
As the COVID-19 outbreak advances worldwide, companies are stepping up to the challenge to develop a potential vaccine. There are over 75 confirmed COVID-19...

Copyright © 2021 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter